News
The funds will support the firm's lead programs, ABS-1230 for KCNT1-related epilepsy and ABS-0871 for TRPV4-positive Charcot-Marie-Tooth disease type 2C.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback